Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.
about
Virus-like particles production in green plantsEvaluation of combinatorial vaccines against anthrax and plague in a murine modelAn RNA element at the 5'-end of the poliovirus genome functions as a general promoter for RNA synthesis.Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.Oral immunogenicity of human papillomavirus-like particles expressed in potato.Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma.CpG DNA: trigger of sepsis, mediator of protection, or both?Production of human papillomavirus type 16 virus-like particles in transgenic plants.Vaccination strategies for the prevention of cervical cancer.Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protectionA live attenuated Salmonella Enteritidis secreting detoxified heat labile toxin enhances mucosal immunity and confers protection against wild-type challenge in chickens.Progress and prospects for L2-based human papillomavirus vaccinesListeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunizationHuman papillomavirus vaccines in plants.Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer.Vaccines for cervical cancer.Route of administration of chimeric BPV1 VLP determines the character of the induced immune responsesThe Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT
P2860
Q24650772-7A85E586-48A2-4A2C-AFD0-D6278A339774Q33283821-DD7167AE-13EF-4907-B5EE-74C2C54E7847Q33598563-8D096C82-35C1-43F6-9251-2355A6149CB4Q33946563-3537AF14-7B93-4F1A-8C20-C6B5DCC1BEECQ35066293-394C08A9-B25B-45BF-9E49-BBDB839AA143Q35182055-DCBEB941-485D-4BF6-A677-070BA00E4592Q35552591-4C0EAB81-94D6-4801-B5CE-851F4F4040B1Q35585084-F349006F-7263-43A5-B767-C3F376C1BE82Q35802720-8696D640-ED7B-4977-A751-E065E8738B32Q36066161-40D8766D-C1FA-45DE-9DF8-BEEF26015E43Q36095558-C650B396-174D-4B22-B683-5648F612B080Q36969236-789B51D6-2269-48D6-94C5-9747ABF0ACECQ37014047-4FD74E4F-EBD2-4355-AC49-C9939CC9D087Q37391175-9C96F1B9-2E16-4899-89F6-0E121856093EQ37776720-45AEAF83-1D02-4AF8-81A3-3151D711CD8DQ38621219-552EC08C-B865-4DF0-8FC0-F41E548945BEQ47604101-0299CEBF-3B28-489C-B606-05B002E10AF7Q56959423-96621DF2-0BE9-46E7-8D36-E81079D7E3ABQ57945015-060A39A4-9BDB-4FD6-AC6E-35FEA90EFFBA
P2860
Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Human papillomavirus virus-lik ...... toxin mutant R192G or CpG DNA.
@ast
Human papillomavirus virus-lik ...... toxin mutant R192G or CpG DNA.
@en
type
label
Human papillomavirus virus-lik ...... toxin mutant R192G or CpG DNA.
@ast
Human papillomavirus virus-lik ...... toxin mutant R192G or CpG DNA.
@en
prefLabel
Human papillomavirus virus-lik ...... toxin mutant R192G or CpG DNA.
@ast
Human papillomavirus virus-lik ...... toxin mutant R192G or CpG DNA.
@en
P2093
P2860
P1433
P1476
Human papillomavirus virus-lik ...... otoxin mutant R192G or CpG DNA
@en
P2093
J D Clements
M DiLorenzo
P2860
P304
P356
10.1128/JVI.75.10.4752-4760.2001
P577
2001-05-01T00:00:00Z